Company intelligence / Profile preview

Lyric Biosciences

United Stateslyrictheatre.com ↗

Ownership: Private
Development stage: Other

01

Overview

Lyric Biosciences has developed a proprietary tissue engineering technology that enables scalable production of human donor-derived immunoglobulins using compact bioreactors. This approach aims to dramatically increase yield per donor and reduce dependence on plasma donations for Ig therapies. No clinical results have been published as of June 2025.

Therapeutic areas: ImmunologyNeurology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on Lyric Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyric Biosciences.

Explore the full profile